We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company posted earnings per share (EPS) of $1.45 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 4.32%. Medtronic beat earnings estimates in each of the trailing four quarters, the average beat being 2.76%.
Q2 Estimates for MDT
The Zacks Consensus Estimate for the company’s fiscal second-quarter revenues is pegged at $9.47 billion, which suggests 5.7% growth from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter earnings stands at $1.34 per share, which implies a 1.5% decrease from the year-ago recorded actuals. The estimate has remained constant in the past 60 days.
Here’s a brief glance at the company’s performance leading up to this announcement.
Key Drivers Likely to Have Shaped MDT’s Q2 Performance
Cardiovascular
The segment is likely to have delivered solid performance in both the U.S. and international markets. Electrophysiology Therapies (“EPT”) may have been a key contributor, aided by continued strength in Cardiac Ablation Solutions (“CAS”). In the fiscal first quarter, Sphere-9 momentum continued, with a 9-point increase in U.S. market share. Medtronic also surpassed $2 billion in trailing 12-month CAS revenues, reaching this milestone ahead of its target time frame.
Growth in the U.S. Affera installed base may have continued in the quarter. Medtronic also secured an expanded CE Mark indication for the Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, opening up another market opportunity. Management expected CAS to outpace the market by more than three times in the fiscal second quarter, with growth likely to moderate over the rest of fiscal 2027 as the company lapped increasingly strong comparisons.
Medtronic may also have benefited from continued strength in its Cardiac Rhythm Management (“CRM”) business. Fiscal second-quarter performance is likely to have been driven by strength across both high-power and low-power therapies, with contributions from EV-ICD, Micra and conduction system pacing, including OmniaSecure.
Within Interventional Cardiology Therapies, both Structural Heart and Coronary and Renal Denervation are expected to have made favorable contributions in the quarter. In Structural Heart, Medtronic continues to advance its internal programs in mitral and tricuspid replacement while expanding its TAVR opportunity through targeted investments in Anteris and Pi-Cardia. Growth in the Coronary business may have been supported by CathWorks, Medtronic's AI and advanced computational science platform for angio-based fractional flow reserve.
Cardiovascular Surgery and Peripheral Vascular Health may also have contributed to the segment's overall growth in the fiscal second quarter.
The Zacks Consensus Estimate projects Cardiovascular revenues to increase 9.6% year over year.
Neuroscience
Within this segment, Cranial & Spinal Technologies (“CST”) is likely to have maintained solid growth, supported by continued adoption of the AiBLE ecosystem of spine implants and enabling technologies, along with strength in Core Spine and Neurosurgery. The newly launched Stealth AXiS platform may also have supported performance, with adoption building and customer feedback remaining positive.
In Specialty Therapies, Neurovascular results globally may have benefited from hemorrhagic and continued strength across flow diversion, intrasaccular embolization, carotid stenting and access devices. Among recent developments, Medtronic completed the acquisition of Scientia Vascular, strengthening its navigation capabilities. The company also received FDA approval for its Onyx 12 Liquid Embolic System to treat subdural hematoma.
Pelvic Health is likely to have maintained strong global growth in the fiscal second quarter, with Altaviva continuing to offset weakness in the broader sacral nerve modulation market.
Meanwhile, Medtronic has expanded its Neuromodulation portfolio through the acquisition of SPR Therapeutics in peripheral nerve stimulation and a distribution agreement with Merit Medical in basivertebral nerve ablation (BVNA). Both markets are growing at more than 20% annually. These trends are likely to have continued in the fiscal second quarter, supporting Neuroscience revenue growth.
The Zacks Consensus Estimate for Neuroscience revenues suggests a 3.8% year-over-year increase.
Medical Surgical (MedSurg)
In the fiscal second quarter, MedSurg is likely to have delivered solid performance, with growth across both U.S. and international markets. Surgical results may have benefited from strength in Advanced Energy and Wound Management, supported by market share gains in LigaSure vessel sealing and V-Loc barbed sutures. Medtronic's Hugo robotic-assisted surgery system is likely to have continued to gain traction, while Endoscopy may have seen continued momentum in the Endoflip 300 system and PillCam.
Acute Care and Monitoring may have been a tailwind as well for the segment, with strong demand for McGRATH video laryngoscopy, Microstream capnography and Nellcor pulse oximetry.
The Zacks Consensus Estimate for MedSurg’s revenues suggests a 1.7% year-over-year increase.
Diabetes
In May 2025, Medtronic announced its intent to separate the Diabetes operating unit, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc. MiniMed completed its initial public offering in March 2026, with Medtronic retaining a controlling financial interest. Its shares began trading on the Nasdaq Global Select Market under the ticker MMED. Medtronic announced the completion of the separation in October, allowing it to focus on its remaining businesses.
In the second quarter of fiscal 2027, the business is likely to have seen strong growth in the U.S. following the commercial launch of MiniMed Flex with Simplera Sync. International growth may have remained healthy, supported by continued adoption of the MiniMed 780G automated insulin delivery system and its Simplera Sync and Instinct sensors.
The Zacks Consensus Estimate suggests Diabetes revenues will grow 12.9% year over year.
Q2 Earnings Whispers for MDT
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Medtronic has an Earnings ESP of -0.75%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat in the upcoming reporting cycle.
BrightSpring Health Services (BTSG - Free Report) has an Earnings ESP of +1.48% and a Zacks Rank #1. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 15.84%.
The Zacks Consensus Estimate for BTSG’s fourth-quarter 2026 EPS implies 69.7% growth from the year-ago reported figure. The consensus mark for fourth-quarter revenues is pegged at $4.28 billion, indicating 20.6% growth year over year.
Pediatrix Medical Group (MD - Free Report) has an Earnings ESP of +1.64% and a Zacks Rank #2. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 9.52%.
The Zacks Consensus Estimate for MD’s fourth-quarter 2026 EPS calls for an increase of 22% from the year-ago quarter’s figure. The consensus mark for revenues stands at $504.5 million, indicating 2.2% growth year over year.
Concentra Group Holdings Parent, Inc. (CON - Free Report) has an Earnings ESP of +1.13% and a Zacks Rank #2. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.85%.
The Zacks Consensus Estimate for CON’s fourth-quarter 2026 EPS suggests an improvement of 3.6% from the year-ago quarter figure. The consensus mark for fourth-quarter revenues is pegged at $569.7 million, calling for a 5.7% jump year over year.
Image: Bigstock
MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results?
Key Takeaways
Medtronic plc (MDT - Free Report) is slated to report its second-quarter fiscal 2027 results on Nov. 24, before the opening bell.
The company posted earnings per share (EPS) of $1.45 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 4.32%. Medtronic beat earnings estimates in each of the trailing four quarters, the average beat being 2.76%.
Q2 Estimates for MDT
The Zacks Consensus Estimate for the company’s fiscal second-quarter revenues is pegged at $9.47 billion, which suggests 5.7% growth from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter earnings stands at $1.34 per share, which implies a 1.5% decrease from the year-ago recorded actuals. The estimate has remained constant in the past 60 days.
Here’s a brief glance at the company’s performance leading up to this announcement.
Key Drivers Likely to Have Shaped MDT’s Q2 Performance
Cardiovascular
The segment is likely to have delivered solid performance in both the U.S. and international markets. Electrophysiology Therapies (“EPT”) may have been a key contributor, aided by continued strength in Cardiac Ablation Solutions (“CAS”). In the fiscal first quarter, Sphere-9 momentum continued, with a 9-point increase in U.S. market share. Medtronic also surpassed $2 billion in trailing 12-month CAS revenues, reaching this milestone ahead of its target time frame.
Growth in the U.S. Affera installed base may have continued in the quarter. Medtronic also secured an expanded CE Mark indication for the Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, opening up another market opportunity. Management expected CAS to outpace the market by more than three times in the fiscal second quarter, with growth likely to moderate over the rest of fiscal 2027 as the company lapped increasingly strong comparisons.
Medtronic PLC Price and EPS Surprise
Medtronic PLC price-eps-surprise | Medtronic PLC Quote
Medtronic may also have benefited from continued strength in its Cardiac Rhythm Management (“CRM”) business. Fiscal second-quarter performance is likely to have been driven by strength across both high-power and low-power therapies, with contributions from EV-ICD, Micra and conduction system pacing, including OmniaSecure.
Within Interventional Cardiology Therapies, both Structural Heart and Coronary and Renal Denervation are expected to have made favorable contributions in the quarter. In Structural Heart, Medtronic continues to advance its internal programs in mitral and tricuspid replacement while expanding its TAVR opportunity through targeted investments in Anteris and Pi-Cardia. Growth in the Coronary business may have been supported by CathWorks, Medtronic's AI and advanced computational science platform for angio-based fractional flow reserve.
Cardiovascular Surgery and Peripheral Vascular Health may also have contributed to the segment's overall growth in the fiscal second quarter.
The Zacks Consensus Estimate projects Cardiovascular revenues to increase 9.6% year over year.
Neuroscience
Within this segment, Cranial & Spinal Technologies (“CST”) is likely to have maintained solid growth, supported by continued adoption of the AiBLE ecosystem of spine implants and enabling technologies, along with strength in Core Spine and Neurosurgery. The newly launched Stealth AXiS platform may also have supported performance, with adoption building and customer feedback remaining positive.
In Specialty Therapies, Neurovascular results globally may have benefited from hemorrhagic and continued strength across flow diversion, intrasaccular embolization, carotid stenting and access devices. Among recent developments, Medtronic completed the acquisition of Scientia Vascular, strengthening its navigation capabilities. The company also received FDA approval for its Onyx 12 Liquid Embolic System to treat subdural hematoma.
Pelvic Health is likely to have maintained strong global growth in the fiscal second quarter, with Altaviva continuing to offset weakness in the broader sacral nerve modulation market.
Meanwhile, Medtronic has expanded its Neuromodulation portfolio through the acquisition of SPR Therapeutics in peripheral nerve stimulation and a distribution agreement with Merit Medical in basivertebral nerve ablation (BVNA). Both markets are growing at more than 20% annually. These trends are likely to have continued in the fiscal second quarter, supporting Neuroscience revenue growth.
The Zacks Consensus Estimate for Neuroscience revenues suggests a 3.8% year-over-year increase.
Medical Surgical (MedSurg)
In the fiscal second quarter, MedSurg is likely to have delivered solid performance, with growth across both U.S. and international markets. Surgical results may have benefited from strength in Advanced Energy and Wound Management, supported by market share gains in LigaSure vessel sealing and V-Loc barbed sutures. Medtronic's Hugo robotic-assisted surgery system is likely to have continued to gain traction, while Endoscopy may have seen continued momentum in the Endoflip 300 system and PillCam.
Acute Care and Monitoring may have been a tailwind as well for the segment, with strong demand for McGRATH video laryngoscopy, Microstream capnography and Nellcor pulse oximetry.
The Zacks Consensus Estimate for MedSurg’s revenues suggests a 1.7% year-over-year increase.
Diabetes
In May 2025, Medtronic announced its intent to separate the Diabetes operating unit, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc. MiniMed completed its initial public offering in March 2026, with Medtronic retaining a controlling financial interest. Its shares began trading on the Nasdaq Global Select Market under the ticker MMED. Medtronic announced the completion of the separation in October, allowing it to focus on its remaining businesses.
In the second quarter of fiscal 2027, the business is likely to have seen strong growth in the U.S. following the commercial launch of MiniMed Flex with Simplera Sync. International growth may have remained healthy, supported by continued adoption of the MiniMed 780G automated insulin delivery system and its Simplera Sync and Instinct sensors.
The Zacks Consensus Estimate suggests Diabetes revenues will grow 12.9% year over year.
Q2 Earnings Whispers for MDT
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Medtronic has an Earnings ESP of -0.75%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat in the upcoming reporting cycle.
BrightSpring Health Services (BTSG - Free Report) has an Earnings ESP of +1.48% and a Zacks Rank #1. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 15.84%.
The Zacks Consensus Estimate for BTSG’s fourth-quarter 2026 EPS implies 69.7% growth from the year-ago reported figure. The consensus mark for fourth-quarter revenues is pegged at $4.28 billion, indicating 20.6% growth year over year.
Pediatrix Medical Group (MD - Free Report) has an Earnings ESP of +1.64% and a Zacks Rank #2. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 9.52%.
The Zacks Consensus Estimate for MD’s fourth-quarter 2026 EPS calls for an increase of 22% from the year-ago quarter’s figure. The consensus mark for revenues stands at $504.5 million, indicating 2.2% growth year over year.
Concentra Group Holdings Parent, Inc. (CON - Free Report) has an Earnings ESP of +1.13% and a Zacks Rank #2. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.85%.
The Zacks Consensus Estimate for CON’s fourth-quarter 2026 EPS suggests an improvement of 3.6% from the year-ago quarter figure. The consensus mark for fourth-quarter revenues is pegged at $569.7 million, calling for a 5.7% jump year over year.